Lipocine (NASDAQ:LPCN) Stock Price Passes Below 200 Day Moving Average – What’s Next?

Lipocine Inc. (NASDAQ:LPCN) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.25 and traded as low as $3.18. Lipocine shares last traded at $3.31, with a volume of 9,502 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Lipocine in a research note on Thursday. They set a “hold” rating on the stock.

Lipocine Price Performance

The stock has a 50 day moving average price of $3.21 and a 200-day moving average price of $4.23. The stock has a market capitalization of $19.05 million, a price-to-earnings ratio of -4.68 and a beta of 1.51.

Institutional Investors Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC grew its stake in Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.